Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tongxiening is a traditional Chinese herbal medicine formulation approved in China for the treatment of irritable bowel syndrome with diarrhea (IBS-D). It is typically administered as granules. Clinical studies have shown that Tongxiening Granules can relieve symptoms of IBS-D and demonstrate efficacy comparable to pinaverium bromide, a standard pharmaceutical treatment for this condition. The mechanism of action is not fully elucidated but is presumed to involve modulation of gastrointestinal function and alleviation of abdominal pain through multiple herbal components. The product has been evaluated in randomized controlled trials and post-marketing studies, showing favorable safety and tolerability profiles[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tongxiening.